Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco Marampon

Showing results (101-110 of 154) with videos related to

Pageof 16
Sort By:
Pharmaceuticals (Basel, Switzerland)|November 27, 2021
Multiple Antitumor Molecular Mechanisms Are Activated by a Fully Synthetic and Stabilized Pharmaceutical Product Delivering the Active Compound Sulforaphane (SFX-01) in Preclinical Model of Human GlioblastomaAlessandro Colapietro, Alessandra Rossetti, Andrea Mancini, et al.
Oncotarget|December 23, 2015
Cyclin D1 silencing suppresses tumorigenicity, impairs DNA double strand break repair and thus radiosensitizes androgen-independent prostate cancer cells to DNA damageFrancesco Marampon, Giovanni Gravina, Xiaoming Ju, et al.
Endocrinology|October 13, 2011
Hormonal therapy promotes hormone-resistant phenotype by increasing DNMT activity and expression in prostate cancer modelsGiovanni Luca Gravina, Francesco Marampon, Margherita Piccolella, et al.
International Journal of Oncology|March 29, 2014
Hypoxia sustains glioblastoma radioresistance through ERKs/DNA-PKcs/HIF-1α functional interplayFrancesco Marampon, Giovanni Luca Gravina, Bianca Maria Zani, et al.
Oncotarget|January 18, 2018
Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancerGiovanni Luca Gravina, Andrea Mancini, Alessandro Colapietro, et al.
Oncotarget|November 8, 2019
Correction: Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancerGiovanni Luca Gravina, Andrea Mancini, Alessandro Colapietro, et al.
Oncotarget|January 27, 2018
Episode-like pulse testosterone supplementation induces tumor senescence and growth arrest down-modulating androgen receptor through modulation of p-ERK1/2, pAR<sup>ser81</sup> and CDK1 signaling: biological implications for men treated with testosterone replacement therapyGiovanni Luca Gravina, Francesco Marampon, Patrizia Sanità, et al.
Biomedicines|May 16, 2023
Abscopal Effect on Bone Metastases from Solid Tumors: A Systematic Review and Retrospective Analysis of Challenge within a ChallengeMiriam Tomaciello, Miriam Conte, Francesca Romana Montinaro, et al.
Journal of Cancer Research and Clinical Oncology|July 1, 2018
Disruption of MEK/ERK/c-Myc signaling radiosensitizes prostate cancer cells in vitro and in vivoCarmela Ciccarelli, Agnese Di Rocco, Giovanni Luca Gravina, et al.
Cells|January 24, 2025
Deciphering the Transcriptional Metabolic Profile of Adipose-Derived Stem Cells During Osteogenic Differentiation and Epigenetic Drug TreatmentGiulia Gerini, Alice Traversa, Fabrizio Cece, et al.
Pageof 16

Showing results (101-110 of 154) with videos related to

Sort By:
Pageof 16
Pharmaceuticals (Basel, Switzerland)|November 27, 2021
Multiple Antitumor Molecular Mechanisms Are Activated by a Fully Synthetic and Stabilized Pharmaceutical Product Delivering the Active Compound Sulforaphane (SFX-01) in Preclinical Model of Human GlioblastomaAlessandro Colapietro, Alessandra Rossetti, Andrea Mancini, et al.
Oncotarget|December 23, 2015
Cyclin D1 silencing suppresses tumorigenicity, impairs DNA double strand break repair and thus radiosensitizes androgen-independent prostate cancer cells to DNA damageFrancesco Marampon, Giovanni Gravina, Xiaoming Ju, et al.
Endocrinology|October 13, 2011
Hormonal therapy promotes hormone-resistant phenotype by increasing DNMT activity and expression in prostate cancer modelsGiovanni Luca Gravina, Francesco Marampon, Margherita Piccolella, et al.
International Journal of Oncology|March 29, 2014
Hypoxia sustains glioblastoma radioresistance through ERKs/DNA-PKcs/HIF-1α functional interplayFrancesco Marampon, Giovanni Luca Gravina, Bianca Maria Zani, et al.
Oncotarget|January 18, 2018
Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancerGiovanni Luca Gravina, Andrea Mancini, Alessandro Colapietro, et al.
Oncotarget|November 8, 2019
Correction: Pharmacological treatment with inhibitors of nuclear export enhances the antitumor activity of docetaxel in human prostate cancerGiovanni Luca Gravina, Andrea Mancini, Alessandro Colapietro, et al.
Oncotarget|January 27, 2018
Episode-like pulse testosterone supplementation induces tumor senescence and growth arrest down-modulating androgen receptor through modulation of p-ERK1/2, pAR<sup>ser81</sup> and CDK1 signaling: biological implications for men treated with testosterone replacement therapyGiovanni Luca Gravina, Francesco Marampon, Patrizia Sanità, et al.
Biomedicines|May 16, 2023
Abscopal Effect on Bone Metastases from Solid Tumors: A Systematic Review and Retrospective Analysis of Challenge within a ChallengeMiriam Tomaciello, Miriam Conte, Francesca Romana Montinaro, et al.
Journal of Cancer Research and Clinical Oncology|July 1, 2018
Disruption of MEK/ERK/c-Myc signaling radiosensitizes prostate cancer cells in vitro and in vivoCarmela Ciccarelli, Agnese Di Rocco, Giovanni Luca Gravina, et al.
Cells|January 24, 2025
Deciphering the Transcriptional Metabolic Profile of Adipose-Derived Stem Cells During Osteogenic Differentiation and Epigenetic Drug TreatmentGiulia Gerini, Alice Traversa, Fabrizio Cece, et al.
Pageof 16